Fig. 6
From: Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine
Seroconversion and protection against challenge induced by sVLPs. Transgenic mice expressing the human PV receptor were immunized intraperitoneally once or twice (2×) with PBS or 0.5 human dose equivalents of IPV or sVLPs (recombinant—“r” or viral construct—“v” expressed) then challenged intramuscularly with wt virus. Graph shows neutralizing antibody titers against PV3 in blood samples taken the day prior to challenge and survival rates following challenge with wt PV3 Saukett. Bars indicate 95% confidence interval (CI) of the geometric mean titer
